Part of the GLP-1RA (Liraglutide, Semiglutide) has been verified to be efficacious in the treatment of fatty liver and is employed in the management of T2DM complicated with nonalcoholic fatty liver disease, primarily by ameliorating metabolic dysfunction, insulin resistance, and lipotoxicity of the organs related to its pathogenesis (61), decelerating the fibrosis process and reducing the liver fat content
Dan Skovronsky, Lillys Chief Scientific and Product Officer, described the results as extraordinary
It is not intended to diagnose, treat, cure, or prevent any disease
Weight loss by Hims is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you
Phase 3 trials are designed to include larger groups and longer follow-up than earlier studies
Jimnez-Acosta F, Ponce-Rodrguez I